Dr. Strosberg on FDA Approval of Lutathera for GEP-NETs

Partner | Cancer Centers | <b>Moffitt Cancer Center</b>

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the FDA approval of Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the FDA approval of Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Related Content:

Moffitt Cancer CenterOncLive TV
Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL
Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL
Dr Gluz on Survival Outcomes With De-Escalated Neoadjuvant Regimens in HR+/HER2+ Early Breast Cancerer